-
王坤
(廣東省人民醫院腫瘤醫院副院長,乳腺腫瘤科主任)
鎖定
王坤專業特長
王坤科研能力
主持和參加10餘項國際、國內多中心臨牀研究,及時掌握國際乳腺癌診治前沿及新動向。主持國家自然基金,廣東省自然基金,廣東省科技計劃及廣東省科技重點研發計劃等課題多項,獲得省科技進步二等獎一項。以第一作者或者通信作者在Clinical Cancer Research、EBioMedicine、International Journal of Cancer和Ther Adv Med Oncol 等雜誌發表SCI文章30餘篇。國家自然基金面上項目評委。
[3-14]
[19]
王坤獎項榮譽
- 2019年國之名醫獲得者。
王坤指南引用情況
王坤學術任職
中國臨牀腫瘤學會(CSCO)乳腺癌專委會常委
中國抗癌協會乳腺癌專業委員會委員
廣東省醫學會乳腺病學分會副主任委員
- 參考資料
-
- 1. 第三屆國之名醫盛典 .健康時報首頁[引用日期2019-11-08]
- 2. 近6000人,首屆中國好醫生榜發佈 .一點資訊[引用日期2019-11-08]
- 3. Multiparametric MRI-based radiomics analysis for prediction of breast cancers insensitive to neoadjuvant chemotherapy .springerlink[引用日期2019-11-14]
- 4. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases. .researchgate[引用日期2019-11-14]
- 5. Application of a carbon nanoparticle suspension for sentinel lymph node mapping in patients with early breast cancer: a retrospective cohort study. .springerlink[引用日期2019-11-14]
- 6. . Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines. .springerlink[引用日期2019-11-14]
- 7. A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer. .springerlink[引用日期2019-11-14]
- 8. Multiparametric MRI-based radiomics analysis for prediction of breast cancers insensitive to neoadjuvant chemotherapy. .springerlink[引用日期2019-11-14]
- 9. Prognostic Significance of Mesenchymal-Epithelial Transition in Triple-Negative Breast Cancers. .europepmc[引用日期2019-11-14]
- 10. Breast lesion characterization using whole-lesion histogram analysis with stretched-exponentialdiffusion model .NCBI[引用日期2019-11-14]
- 11. DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations - PubMed .Pubmed[引用日期2022-02-28]
- 12. Anthracycline-containing versus carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial - PubMed .Pubmed[引用日期2022-02-28]
- 13. The role of adjuvant chemotherapy in stage I-III male breast cancer: a SEER-based analysis - PubMed .Pubmed[引用日期2022-02-28]
- 14. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial - PubMed .Pubmed[引用日期2022-02-28]
- 15. 我院乳腺腫瘤科MDT團隊勇奪國家癌症中心MDT大賽全國總冠軍 .廣東省人民醫院[引用日期2022-02-28]
- 16. 王坤主任率領團隊再奪乳腺癌MDT大賽全國總冠軍-廣東省人民醫院 .廣東省人民醫院[引用日期2022-02-28]
- 17. 中國數據登上國際舞台 王坤教授團隊研究成果被NCCN指南引用 .廣東省人民醫院[引用日期2022-02-28]
- 18. Clinical practice guidelines for sentinel lymph node biopsy in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021 - PubMed .Pubmed[引用日期2022-02-28]
- 19. 廣東省人民醫院 .廣東省人民醫院[引用日期2022-03-14]
- 20. 廣東省人民醫院 .廣東省人民醫院[引用日期2022-03-14]
- 21. 2022年第二季度“廣東好人”名單公示 .大洋網[引用日期2022-10-01]
- 22. 關於表彰2022年第二季度 “廣東好人”的通報 .廣東文明網[引用日期2022-10-14]
- 23. 2024年廣東省五一勞動獎擬表彰對象公示 .廣州日報[引用日期2024-05-07]
- 收起